fig2
From: Combinatorial treatment of curcumin or silibinin with doxorubicin sensitises high-risk neuroblastoma
![Combinatorial treatment of curcumin or silibinin with doxorubicin sensitises high-risk neuroblastoma](https://image.oaes.cc/14a5c1e3-b602-421d-81e3-4f667c3ea1c7/3386.fig.2.jpg)
Figure 2. Curcumin and silibinin reduced the expression of the mesenchymal marker N-Cadherin. A: Western blot analysis for N-Cadherin in SK-N-BE2 cells; B: Western blot analysis for N-Cadherin in SH-N-AS cells; C: Western blot analysis for N-Cadherin in IMR32 cells. Drug concentration: 10 μM curcumin or 100 μM silibinin. β-actin was used the loading control. The N-cadherin band intensities are normalised to respective band intensities of β-actin